瘤标记基因测试的诊断性能,以个性化血清CA19-9参考范围
Mohamad Dbouk1, Toshiya Abe1, Chiho Koi1
1Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland.
概括
使用fucosyltransferase (FUT) 基因变异个性化癌症标志物CA19-9参考范围显著提高了胰腺管道腺癌的诊断准确性. 这种方法增强了测试的性能.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 生物化学 生物化学
背景情况:
- CA19-9是一种瘤标志物,受可转移酶 (FUT) 酶变体的影响.
- 基转移酶 (FUT) 酶FUT3和FUT2是CA19-9合成中的关键.
- 在FUT酶的遗传变异影响CA19-9水平和诊断效用.
研究的目的:
- 开发和评估一种临床测试,以检测福科西转移酶 (FUT) 变异.
- 为了评估本FUT变种测试的胰腺管道腺癌 (PDAC) 诊断性能.
- 为了确定FUT变种测试是否可以提高PDAC的CA19-9诊断准确度.
主要方法:
- 开发了一种用于检测FUT3和FUT2变体的临床测试.
- 从234个PDAC病例 (测试组) 和134个PDAC病例 (验证组) 收集了样本.
- 利用接收器运行特征 (ROC) 曲线分析来比较单独的CA19-9与与FUT基因测试结合的CA19-9.
主要成果:
- 标准CA19-9切线显示了68.8%的灵敏度和91.4%的特异性.
- 基于FUT组的个性化CA19-9切割值提高了特异性,达到98.9%.
- 单单CA19-9的曲线下的面积 (AUC) 为0.84;在FUT基因测试中,AUC提高到0.92 (P < 0.001).
结论:
- 使用FUT基因变异个性化CA19-9参考范围显著提高了PDAC的诊断准确性.
- FUT变异测试提供了一种更精确的方法来解释癌症诊断中的CA19-9水平.
- 这种个性化的方法有望提高CA19-9在瘤学的临床效用.
相关概念视频
Serum Laboratory Studies, Stool Test, Breath Test
378
Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
378
Serum Studies: Renal Function Tests
23
Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
23


